PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Ceftazidime

Drugs in development · updated 30 October 2026

Ceftazidime: clinical trials and development status

Other names and codes: Ceptaz, Fortaz In Plastic Container, Fortaz

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 23 June 2016

As of 30 October 2026 Ceftazidime is in 4 active clinical trials (recruiting or ongoing, phases I–III) for 10 diseases. The most advanced phase is III.

4Active trials
IIIMost advanced phase
10Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Ceftazidime and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
SepsisIII1NCT07063095
Septic shockIII1NCT07063095
AnaphylaxisII1NCT06406114
Bacterial meningitisII1NCT07431307
Drug HypersensitivityII1NCT06406114
Febrile neutropeniaII1NCT07842198
HypersensitivityII1NCT06406114
Infection of the central nervous systemII1NCT07431307
Multiple myelomaII1NCT07842198
VentriculitisII1NCT07431307

Everything on Ceftazidime

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch